Antag Therapeutics ApS: Financial statements 2023
CVR: 38402056
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Antag Therapeutics ApS (CVR 38402056) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -13,707,565 and a net result of DKK -13,811,394 compared with DKK -9,784,355 the year before. Equity in the 2023 report amounted to DKK -9,172,591. The company had 2 employees in the financial year.
- Gross Profit
- DKK -13,707,565
- Profit/Loss
- DKK -13,811,394
- Equity
- DKK -9,172,591
- Total Assets
- DKK 23,970,326
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -13.7M | -13.8M | -9.2M | 2 |
| 2022 | - | -9.9M | -9.8M | 4.6M | 2 |
| 2021 | - | -13.1M | -14.9M | 10.9M | 6 |
| 2020 | - | -10.9M | -12.4M | -9.8M | 7 |
| 2019 | - | -7.9M | -9.2M | 2.6M | 4 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of September 13, 2023, Jayson Dallas has left the board of directors of Antag Therapeutics ApS.
As of September 12, 2023, Thomas Edward Needham Jr. has left the board of directors of Antag Therapeutics ApS.
Antag Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -9,904,462, and the net result was DKK -9,784,355.
As of June 1, 2023, Mark Currie has joined the board of directors of Antag Therapeutics ApS.
As of June 1, 2023, Jayson Dallas has joined the board of directors of Antag Therapeutics ApS.
As of June 1, 2023, Kirsten Aarup Drejer has left the board of directors of Antag Therapeutics ApS.
As of June 1, 2023, Christine Theresa Fischette has left the board of directors of Antag Therapeutics ApS.
About Antag Therapeutics ApS
Antag Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Antag Therapeutics IVS. The management consists of Philip Just Larsen. The board consists of Keith Richard Leonard Jr (chair), Alexander Volker Wilhelm Mayweg, Amit Kantilal Shah and Jørgen Søberg Petersen. The company's owners include Novo Holdings A/S, Dawn Holdco SCSp and Versant Venture Capital VII, L.P.. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -191,588,449 and a net result of DKK -200,999,582 compared with DKK -32,265,249 the year before. Equity in the 2025 report amounted to DKK 235,310.